Search clinical trials for: Fluticasone

Total 766 results

Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
GlaxoSmithKline

Completed

A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole

Asthma

United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.
PPD

Completed

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Asthma

United States, Bulgaria, Croatia, Hungary, Israel, Poland, Serbia, Spain, Ukraine
GlaxoSmithKline

Completed

Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

Asthma
Assiut University

Unknown

Radiologic Scoring of Patients With Chronic Sinusitis and Nasal Polyps

Chronic Sinusitis

Egypt
Brigham and Women's Hospital
Massachusetts General Hospital; Baim Institute for Clinical Research

Terminated

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations (GABLE)

Asthma

United States
GlaxoSmithKline

Completed

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product

Asthma

Finland, Belgium, France, Netherlands, Sweden, Estonia, Germany, Spain, Latvia, Italy
Henan University of Traditional Chinese Medicine

Unknown

Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE)

Asthma

United States
GlaxoSmithKline

Completed

A Dose-ranging Study of Fluticasone Furoate (FF)

Asthma

United States, Germany, Japan, Russian Federation, Bulgaria, Peru, Philippines, Poland, Mexico, Ukraine, Sweden, South Africa, Latvia, Puerto Rico, Georgia
GlaxoSmithKline

Completed

Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler

Asthma

Germany
GlaxoSmithKline

Terminated

Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting

Rhinitis, Allergic, Seasonal | Seasonal Allergic Rhinitis
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Asthma

Japan
GlaxoSmithKline

Completed

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Asthma
GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma

Asthma

Russian Federation, Ukraine
GlaxoSmithKline

Completed

Drug Use Investigation for ALLERMIST

Rhinitis
GlaxoSmithKline

Completed

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis

Sinusitis, Acute

Germany, Spain, Bulgaria, Czechia, Canada, Sweden, Netherlands, Estonia, Norway, Poland, Ukraine, Russian Federation
GlaxoSmithKline

Completed

Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
GlaxoSmithKline

Completed

Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination

Pulmonary Disease, Chronic Obstructive

Australia
GlaxoSmithKline

Completed

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

Rhinitis, Allergic, Perennial and Seasonal

Australia
GlaxoSmithKline
Hammersmith Medicines Research

Completed

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma

Asthma

New Zealand
Ramathibodi Hospital

Completed

Nebulized Corticosteroid for Post Extubation Stridor in Children

Stridor

Thailand
Johns Hopkins University
GlaxoSmithKline; American Lung Association

Completed

Long-acting Beta Agonist Step Down Study (LASST)

Asthma

United States
Novartis Pharmaceuticals

Withdrawn

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (GLOW8)

Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals

Completed

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD (COMBINE)

Chronic Obstructive Pulmonary Disease

Argentina, Dominican Republic, Panama, Mexico, Brazil, Chile, Ecuador, Honduras
GlaxoSmithKline

Completed

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Rhinitis, Allergic, Perennial

Thailand
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Chronic Obstructive Pulmonary Disease (FUTURE)

Chronic Obstructive Pulmonary Disease

Italy
Chiesi Farmaceutici S.p.A.

Completed

FACTO Study (Foster® As Complete Treatment Option) (FACTO)

Asthmatic Patients

Spain, France, Germany, Netherlands
Chiesi Farmaceutici S.p.A.

Completed

Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma (FORTE)

Asthma

Ukraine, Bulgaria, Italy
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Asthma (NELSON)

Asthma

Italy
National Jewish Health
GlaxoSmithKline

Terminated

Evaluating Genes in Sputum to Measure Drug Response in COPD

Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
Sandoz

Completed

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

Asthma

United States
Mundipharma Research Limited

Completed

Flutiform® Compared With Seretide® in the Treatment of COPD

Chronic Obstructive Pulmonary Disease

China, Taiwan, Korea, Republic of, New Zealand, Australia
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
GlaxoSmithKline

Completed

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Asthma

United States
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Pulmonary Disease, Chronic Obstructive

Germany, United States, Korea, Republic of, Czech Republic
Novartis Pharmaceuticals

Terminated

Study of Safety of Foradil in Patients With Persistent Asthma

Persistent Asthma

United States
Novartis Pharmaceuticals

Completed

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Asthma

Germany, United States, Belgium, Colombia, Czech Republic, India, Korea, Republic of, Poland, Romania, South Africa
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Individualized Therapy For Asthma in Toddlers (INFANT)

Asthma | Wheezing

United States
Egalet Ltd

Completed

Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects

Healthy Subjects

United Kingdom
GlaxoSmithKline

Completed

Treatment Of Symptomatic Asthma In Children

Asthma

Netherlands
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
Novartis

Completed

Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients

Asthma

Germany, India

3

Subscribe